Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer

被引：0
|
作者：
Kathryn Lurain
Ramya Ramaswami
Robert Yarchoan
Thomas S. Uldrick
机构：
[1] National Institutes of Health,HIV & AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute
[2] Fred Hutchinson Cancer Research Center,Division of Global Oncology, Department of Medicine
[3] Fred Hutchinson Cancer Research Center,Vaccine and Infectious Disease Division
[4] Fred Hutchinson Cancer Research Center,Clinical Research Division
[5] University of Washington,Medical Oncology Division
来源：
Current HIV/AIDS Reports | 2020年 / 17卷
关键词：
PD-1; PD-L1; Checkpoint inhibitors; HIV; Cancer; T cell exhaustion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：547 / 556
页数：9
相关论文
共 50 条
  • [31] An Imaging-Based Assay to Measure the Location of PD-1 at the Immune Synapse for Testing the Binding Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies
    Zhong, Justin C.
    Lerrer, Shalom
    Mor, Adam
    BIO-PROTOCOL, 2024, 14 (17):
  • [32] Comparative analysis of pharmacokinetics and antitumor effect between anti-PD-1 and anti-PD-L1 in mice models
    Hatakeyama, Hiroto
    Kurino, Taiki
    Suzuki, Hiroyuki
    Terui, Ayu
    Uehara, Tomoya
    Arano, Yasushi
    Hisaka, Akihiro
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [33] Early predictive factors and biomarkers for the response to immunological checkpoint inhibitors (anti-PD-1 and anti-PD-L1)
    Colle, E.
    Andre, T.
    Lebbe, C.
    Borg, C.
    ONCOLOGIE, 2016, 18 (9-10) : 533 - 542
  • [34] Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1
    Perez-Santos, Martin
    Anaya-Ruiz, Maricruz
    Cebada, Jorge
    Herrera-Camacho, Irma
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2019, 29 (05) : 311 - 314
  • [35] Benefit with anti-PD-L1
    Diana Romero
    Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
  • [36] Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
    Sun, J.
    Yang, Q.
    Chen, M.
    Gu, J.
    Zheng, L.
    Yu, Y.
    Li, F.
    Zhang, L.
    Niu, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S451 - S451
  • [37] Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies
    Tang, Jun
    Pearce, Laura
    O'Donnell-Tormey, Jill
    Hubbard-Lucey, Vanessa M.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [38] Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
    Liu, Hao
    Liu, Yanli
    Zhao, Zhen
    Li, Yuanke
    Mustafa, Bahaa
    Chen, Zhijin
    Barve, Ashutosh
    Jain, Akshay
    Yao, Xiaolan
    Li, Guangfu
    Cheng, Kun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [39] The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
    Chen, Xiao-Jiang
    Yuan, Shu-Qiang
    Duan, Jin-Ling
    Chen, Yong-Ming
    Chen, Shi
    Wang, Yun
    Li, Yuan-Fang
    DISEASE MARKERS, 2020, 2020
  • [40] Combination of ANTI-PD-1/ANTI-PD-L1 Antibodies With the Distinct Character Exerts Preferable Anti-Tumor Immune Cycle in a Murine Neuroblastoma Model
    Inoue, S.
    Horiuchi, Y.
    Setoyama, Y.
    Takeuchi, Y.
    Murakami, T.
    Odaka, A.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S157 - S157
12345